Latest Healthcare News

Talius Group reports a robust December quarter with $4.4 million revenue, positive operating cash flow, and a strategic $2.5 million capital raise, positioning the company for strong growth in 2025 amid evolving aged care legislation.

Hydrix Limited has extended its contract with Paul Hartmann AG, adding $2.8 million in revenue and reinforcing its international growth strategy.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.

FleetPartners Group Limited reported strong FY24 results with record new business writings and assets under management, underpinning a robust growth trajectory and a significant $30 million share buy-back announced for 1H25.

Cyclopharm has inked a pivotal three-year agreement with HCA Healthcare, enabling deployment of its Technegas® lung imaging technology across up to 169 US nuclear medicine departments. This deal marks a major step in expanding Technegas®’ footprint in the American healthcare market.

Australian Foundation Investment Company (AFIC) reported a 2.7% rise in half-year profit to $154.2 million and increased its interim dividend to 12 cents per share, while its portfolio outpaced the S&P/ASX 200 over the past year.

Compumedics has locked in a pivotal five-year contract with Philips Australia, cementing Somfit as the leading device for pharmacy-based sleep testing and underpinning significant SaaS revenue growth through 2028.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.

Pacific Edge reports stable test volumes in Q3 FY25 despite Medicare reimbursement uncertainties and seasonal slowdowns, while gearing up for legal action against a flawed Medicare coverage decision.

Global Health Limited reported a robust 22% increase in customer receipts for the December 2024 quarter, alongside a significant improvement in operating cash flow, positioning the company well amid ongoing healthcare sector challenges.